Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Public ClinicalTrials.gov record NCT02201901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) with and without ribavirin (RBV) for 12 weeks and SOF/VEL FDC for 24 weeks in adults with chronic hepatitis C virus (HCV) infection and Child-Pugh-Turcotte (CPT) class B cirrhosis.
Study identification
- NCT ID
- NCT02201901
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 268 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2014 (Type not available)
- Primary completion
- Aug 2015 (Actual)
- Completion
- Nov 2015 (Actual)
- Last update posted
- Nov 15, 2018
2014 – 2015
United States locations
- U.S. sites
- 49
- U.S. states
- 27
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Los Angeles | California | 90048 | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Pasadena | California | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Jacksonville | Florida | 32256 | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Indianapolis | Indiana | 46237 | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | Monroe | Louisiana | 71280 | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Jackson | Mississippi | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Santa Fe | New Mexico | 87505 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | Chapel Hill | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | 28204 | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Providence | Rhode Island | 02905 | — |
| Not listed | Germantown | Tennessee | 38138 | — |
| Not listed | Nashville | Tennessee | 37211 | — |
| Not listed | Arlington | Texas | 76012 | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Murray | Utah | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Norfolk | Virginia | 23502 | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02201901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 15, 2018 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02201901 live on ClinicalTrials.gov.